source
- Novo to pay Hengrui up to $2.6 billion for rights to weekly obesity pill HRS-1596Novo announced a deal with China-based Hengrui Pharma, paying $300 million up front for rights to HRS-1596, a once‑weekly obesity pill. The agreement could rise to $2.6 billion if the candidate me…
- ai3Bio raises $48 million to develop T-helper cell-targeted immune-reset therapiesai3Bio, a new biotech startup formed from Corner Therapeutics and Novasenta, announced it has secured $48 million in an early-stage venture capital round. The company aims to create treatments for…